BCL-XL knockdown using siRNA (siBCL-XL) significantly increased apoptosis induction (Fig. 4d) and decreased viability of ALK-rearranged lung cancer cells, compared to those treated with alectinib alone (Fig. 4e). The gene discussed is BCL2L1; the disease is lung carcinoma.